GERN Geron Corporation - Common Stock

NASDAQ · Biotechnology · SEC EDGAR पर देखें ↗
$1.58
मूल्य · अग 19, 2026
मौलिकता इस प्रकार है अग 5, 2026
52W रेंज
$1–$2
55% of range
विश्लेषक रेटिंग
BUY
11 analysts
मूल्य लक्ष्य
$4
+170% upside
P/E (TTM)
-0.0
ROE
-34.4%
शुद्ध लाभ मार्जिन
—

Geron Corporation - Common Stock के बारे में विकिपीडिया से कंपनी का अवलोकन

Geron Corporation is a biotechnology company located in Foster City, California which specializes in developing and commercializing therapeutic products for cancer that inhibit telomerase.

और पढ़ें

Geron Corporation is a biotechnology company located in Foster City, California which specializes in developing and commercializing therapeutic products for cancer that inhibit telomerase.

Company information

Geron, based in Foster City, California, was founded by gerontologist Mary C. West and Michael D. West, now CEO of AgeX Therapeutics. They secured initial venture capital investments in the company from Kleiner Perkins Caufield & Byers and Venrock. The company was incorporated in 1990 and began doing business in 1992. John A. Scarlett was appointed CEO in 2011.

The company's Scientific and Clinical Advisory Board has included Nobel laureates James Watson, Gunter Blobel, and Carol Greider, and Leonard Hayflick, known for discovering that human cells divide for a limited number of times in vitro (called the Hayflick limit).

In 2017, Geron staff received the highest median pay in California, at $500,250.

Drug candidates

Cancer therapies

Geron Corporation has sponsored human clinical trials of several potential anti-cancer products.

Imetelstat (GRN163L) is a drug that targets telomerase. In studies conducted at Johns Hopkins University, GRN163L was active against both CD138+ and CD138neg cancer stem cells and eliminated the colony forming potential of both by five weeks. Similarly, GRN163L inhibited the in vitro clonogenic growth of CD138neg Multiple Myeloma Cancer Stem Cells isolated from the bone marrow aspirates of patients with multiple myeloma. On November 3, 2014, the FDA removed the full clinical hold on imetelstat and declared the company's clinical development plan as acceptable. In 2014, Geron licensed imetelstat to Janssen Biotech. In 2017, imetelstat was granted fast track status by the FDA for certain patients with myelodysplastic syndrome. In 2018, Janssen Biotech returned the rights to imetelstat to Geron. Imetelstat is currently in two Phase 3 trials: NCT02598661, a study of the drug's ability to reduce the transfusion requirements of patients with myelodysplastic syndrome (MDS), and NCT04576156, an investigation of the drug's effect on the overall survival of patients with myelofibrosis.

A trial of GRNVAC1, a telomerase vaccine being used on patients with prostate cancer was carried out at Duke University. Geron's progress with telomerase vaccines attracted a modest monetary investment in 2005 from Merck.

GRN1005, an LRP-directed conjugate of paclitaxel, was in phase II clinical trials for brain cancer but discontinued based on preliminary results in 2012.

Telomerase activation

In addition to testing drug candidates that exploit cancer cell's dependence on telomerase, Geron is researching the possible applications of activating the enzyme in normal cells to delay cellular senescence. The company is in the early stages of developing a telomerase based treatment for HIV called TAT0002, which is the saponin cycloastragenol in Chinese herb Astragalus propinquus. Geron has granted a license to Telomerase Activation Sciences to sell TA-65, the telomerase activator agent also derived from astragalus. In October 2010 Intertek/AAC Labs, an ISO 17025 internationally recognized lab, found the largest component of TA-65 to be cycloastragenol.

Geron originally investigated telomerase as a means of understanding and modifying human aging. However, Geron has ceased aging research of any kind.

Stem cell therapies

On January 23, 2009, Geron received FDA approval to begin Phase I testing of GRNOPC1 in humans. GRNOPC1 is an embryonic stem cell based drug that is designed to treat specific forms of spinal cord injury through remyelination of damaged axons. This trial does not involve direct use of stem cells however, as GRNOPC1 is composed of oligodendrocyte progenitor cells derived from embryonic stem cell lines. Studies have shown significant restoration of mobility in animals with spinal injuries that received cells.

Geron also has several other embryonic stem cell treatments that are still in the preclinical phase, including GRNCM1, a treatment for heart disease, and GRNIC1, a treatment for diabetes. In tests with diabetic mice, 80% of the mice given GRNIC1 were still alive in 50 days while the entire control group, which was given no treatment, perished.

Geron sold its human stem cell research assets to Asterias in 2013.

GRNOPC1

As of October 2010 and November 2010, one of Geron's most highly publicized trial therapy products has been GRNOPC1, a stem cell therapy designed to heal severe spinal cord injuries. The cells in the GRNOPC1 therapy have been coaxed into becoming early myelinated glial cells, a type of cell that insulates nerve cells. For every GRNOPC1 cell that is injected in the patient, they become six to ten cells in a few months.

In October 2011 updated results on four patients were released. The trial was discontinued in Nov 2011.

In early 2013 BioTime, whose CEO at the time was Geron founder Michael D. West, acquired 400 patents and other intellectual property related to embryonic stem cells from Geron and later went on to restart the trial.

Patent issues

Geron Corporation initially held exclusive rights to three cell types derived from embryonic stem cells, as the result of paying for the research originally conducted by Dr. James Thomson at the University of Wisconsin–Madison. The patents on the other three cell types are owned by the Wisconsin Alumni Research Foundation (WARF). WARF and Geron did not charge academics to study human stem cells but did charge commercial users. In 2001 WARF came under public pressure to widen access to human stem-cell technology, and they launched legal action against Geron Corporation to recover some of the previously sold rights. The two sides agreed that Geron would keep the rights to only three cell types.

In October 2006, a legal challenge was mounted to overturn these patents by The Foundation for Taxpayer and Consumer Rights and the non-profit patent-watchdog Public Patent Foundation. They contended that two of the patents granted to WARF are invalid because they cover a technique published in 1992 for which a patent had already been granted to an Australian researcher. Another part of the challenge came from the molecular biologist Jeanne Loring who stated that University of Wisconsin–Madison stem cell pioneer James Thomson's techniques (currently patents held by WARF) are rendered obvious by a 1990 paper and two textbooks. The outcome of this legal challenge was particularly relevant to the Geron Corporation as it can only license patents that are upheld. The patents were ultimately upheld when the reexamination concluded in 2008.

As an interim measure, on January 23, 2007, WARF relaxed the stem cell patents, allowing industry-sponsored research at academic and non-profit institutions without a license. WARF will allow easier and simpler cost free cell transfers among researchers and would not require a license or agreement from California's taxpayer-funded stem cell research program.

Politics

As a participant in the then-controversial stem cell and cloning area, Geron Corporation was asked to testify about its technology before the U.S. Congress. In 2001, when Congress was attempting to ban all forms of cloning, then Geron CEO Thomas Okarma spoke before Congress to preserve cloning for therapeutic purposes.

स्रोत: विकिपीडिया (अंग्रेज़ी), CC BY-SA 4.0 · विकिपीडिया पर देखें ↗

Wikidata ↗

GERN स्टॉक स्नैपशॉट मूल्य, बाजार पूंजीकरण, P/E, EPS, ROE, ऋण/इक्विटी, 52-सप्ताह की सीमा

मूल्य
$1.57
मार्केट कैप
$1M
P/E (TTM)
-0.0
EPS (TTM)
$-0.13
राजस्व (TTM)
$237.0K
लाभांश प्रतिफल
—
ROE
-34.4%
D/E ऋण/इक्विटी
0.5
52W रेंज
$1 – $2

GERN स्टॉक मूल्य चार्ट तकनीकी संकेतकों के साथ दैनिक OHLCV — पैन, ज़ूम और अपना दृश्य कस्टमाइज़ करें

10-वर्षीय प्रदर्शन राजस्व, शुद्ध आय, मार्जिन और ईपीएस रुझान

राजस्व और शुद्ध आय $237.0K
8-point trend, -96.2%
2016-12-31 → 2023-12-31
EPS $-0.13
8-point trend, +31.6%
2016-12-31 → 2025-12-31
फ्री कैश फ्लो —
8-point trend, -1090.2%
2016-12-31 → 2024-12-31
मार्जिन —

मूल्यांकन P/E, P/S, P/B, EV/EBITDA अनुपात — क्या स्टॉक महंगा है या सस्ता?

मेट्रिक
5Y रुझान
GERN
सहकर्मी माध्यिका
P/E (TTM)
5-point trend, -191.3%
-0.0
—
P/S (TTM)
5-point trend, -98.2%
0.0
12.8
P/B
5-point trend, +19.7%
0.0
3.4
EV / EBITDA
5-point trend, -259.5%
-0.6
—

लाभप्रदता सकल, परिचालन और शुद्ध मार्जिन; ROE, ROA, ROIC

मेट्रिक
5Y रुझान
GERN
सहकर्मी माध्यिका
ROA
5-point trend, +69.3%
-14.3%
-31.3%
ROE
5-point trend, +58.8%
-34.4%
-38.1%
ROIC
2-point trend, +54.5%
-19.9%
—

वित्तीय स्वास्थ्य ऋण, तरलता, शोधन क्षमता — बैलेंस शीट की मजबूती

मेट्रिक
5Y रुझान
GERN
सहकर्मी माध्यिका
Debt / Equity (ऋण / इक्विटी)
5-point trend, +34.3%
0.5
—
Current Ratio (वर्तमान अनुपात)
5-point trend, +13.4%
4.7
10.9
Quick Ratio (त्वरित अनुपात)
5-point trend, +34.1%
1.0
—

विकास राजस्व, EPS और शुद्ध आय वृद्धि: YoY, 3Y CAGR, 5Y CAGR

मेट्रिक
5Y रुझान
GERN
सहकर्मी माध्यिका
Revenue YoY (राजस्व YoY)
5-point trend, -48.5%
-60.2%
—
Revenue CAGR 3Y (राजस्व CAGR 3Y)
5-point trend, -48.5%
-2.1%
—

प्रति शेयर मेट्रिक्स EPS, प्रति शेयर बुक वैल्यू, प्रति शेयर नकदी प्रवाह, प्रति शेयर लाभांश

मेट्रिक
5Y रुझान
GERN
सहकर्मी माध्यिका
EPS (Diluted) (EPS (तनुभूत))
5-point trend, +62.9%
$-0.13
—

पूंजी दक्षता एसेट टर्नओवर, इन्वेंटरी टर्नओवर, प्राप्य टर्नओवर

मेट्रिक
5Y रुझान
GERN
सहकर्मी माध्यिका

GERN विश्लेषक सर्वसम्मति तेजी और मंदी के विश्लेषक राय, 12-महीने का मूल्य लक्ष्य, अपसाइड

खरीदें 11 विश्लेषक
  • मजबूत खरीद 4 36.4%
  • खरीदें 5 45.5%
  • होल्ड 2 18.2%
  • बेचें 0 0.0%
  • मजबूत बिक्री 0 0.0%

12-महीने का मूल्य लक्ष्य

4 विश्लेषक · 2026-08-17
मध्यिका लक्ष्य $4.00 +154.0%
माध्य लक्ष्य $4.25 +169.8%

Earnings History EPS वास्तविक बनाम अनुमान, आश्चर्य %, बीट दर, अगली आय तिथि

औसत आश्चर्य
0.01%
Period EPS Actual EPS अनुमान आश्चर्य
30 जून 2026 $-0.02 $-0.01 -0.01%
31 मार्च 2026 $-0.01 $-0.02 0.01%
31 दिसमबर 2025 $-0.02 $-0.03 0.01%
30 सितमबर 2025 $-0.03 $-0.03 0.00%
30 जून 2025 $-0.02 $-0.03 0.01%
31 मार्च 2025 $-0.03 $-0.04 0.01%

सहकर्मी तुलना (GICS उप-उद्योग) प्रमुख मेट्रिक्स बनाम सेक्टर के साथी

टिकर मार्केट कैप P/E राजस्व YoY शुद्ध मार्जिन ROE सकल मार्जिन
GERN $845M -10.2 -60.2% — -34.4% —
AVTX $336M -3.1 -86.6% -132642.4% -83.4% —
JANX $833M -7.5 -5.5% -1136.2% -11.7% —
ANNX $750M -3.7 — — -100.7% —
SLDB $445M -2.8 — — -79.5% —
ARDX $1.42B -22.4 22.1% -15.1% -40.2% —
CADL $310M -7.8 — — -53.7% —
DSGN $567M -7.7 — — -32.8% —
CLYM $191M -4.5 — — -34.6% —
OLMA $2.03B -13.4 — — -39.4% —

पूर्ण मौलिक सभी मेट्रिक्स प्रति वर्ष — आय विवरण, बैलेंस शीट, नकदी प्रवाह

आय विवरण 15
GERN के लिए वार्षिक आय विवरण डेटा
मेट्रिक रुझान 202520242023202220212020201920182017201620152014
Revenue 10-point trend, -79.4% · · $237.0K $596.0K $1M $253.0K $460.0K $1M $1M $6M $36M $1M
SG&A Expense 12-point trend, +850.3% $159M $146M $69M $44M $30M $26M $21M $19M $19M $19M $18M $17M
Operating Expenses 12-point trend, +573.9% $252M $251M $194M $139M $115M $77M $73M $32M $30M $37M $37M $37M
Operating Income 12-point trend, -88.9% $-69M $-174M $-194M $-139M $-114M $-77M $-73M $-31M $-29M $-31M $-559.0K $-36M
Interest Expense 5-point trend, +2334.7% · $19M $8M $7M $4M $760.0K · · · · · ·
Interest Income 8-point trend, +457.3% $18M $20M $18M $3M $527.0K $2M $4M $3M · · · ·
Other Non-op 8-point trend, -228.9% $-375.0K $-236.0K $-23.0K $1M $1M $168.0K $-69.0K $-114.0K · · · ·
Pretax Income 4-point trend, +41.2% $-83M $-175M $-182M $-142M · · · · · · · ·
Income Tax 3-point trend, +240.9% $75.0K $449.0K $22.0K · · · · · · · · ·
Net Income 12-point trend, -134.1% $-84M $-175M $-184M $-142M $-116M $-76M $-69M $-27M $-28M $-30M $46.0K $-36M
EPS (Basic) 10-point trend, +43.5% $-0.13 $-0.27 $-0.32 $-0.37 $-0.35 $-0.28 · · $-0.18 $-0.19 $0.00 $-0.23
EPS (Diluted) 10-point trend, +43.5% $-0.13 $-0.27 $-0.32 $-0.37 $-0.35 $-0.28 · · $-0.18 $-0.19 $0.00 $-0.23
Shares (Basic) 10-point trend, +334.2% 666,662,989 646,033,247 570,645,405 380,784,846 327,631,814 271,460,265 · · 159,224,986 159,045,644 158,036,162 153,540,341
Shares (Diluted) 10-point trend, +334.2% 666,662,989 646,033,247 570,645,405 380,784,846 327,631,814 271,460,265 · · 159,224,986 159,045,644 162,663,894 153,540,341
EBITDA 12-point trend, -88.9% $-69M $-174M $-194M $-139M $-114M $-77M $-73M $-31M $-29M $-31M $-559.0K $-36M
बैलेंस शीट 24
GERN के लिए वार्षिक बैलेंस शीट डेटा
मेट्रिक रुझान 202520242023202220212020201920182017201620152014
Cash & Equivalents 12-point trend, +81.2% $78M $79M $70M $57M $35M $10M $14M $11M $16M $13M $21M $43M
Short-term Investments 4-point trend, -27.9% · · · · · · · · $78M $102M $93M $109M
Receivables 2-point trend, +2.9% $37M $36M · · · · · · · · · ·
Inventory 2-point trend, +201.3% $117M $39M · · · · · · · · · ·
Prepaid Expense 12-point trend, +526.4% $5M $5M $5M $4M $1M $2M $1M $1M $580.0K $524.0K $647.0K $736.0K
Current Assets 12-point trend, +239.1% $520M $491M $341M $180M $187M $200M $142M $166M $96M $116M $116M $153M
PP&E (Net) 12-point trend, +411.0% $884.0K $1M $1M $793.0K $650.0K $658.0K $408.0K $59.0K $102.0K $183.0K $207.0K $173.0K
PP&E (Gross) 12-point trend, +126.7% $3M $3M $2M $2M $1M $1M $1M $838.0K $822.0K $1M $1M $1M
Accum. Depreciation 12-point trend, +85.4% $2M $2M $1M $896.0K $650.0K $613.0K $843.0K $779.0K $720.0K $1M $1M $1M
Other Non-current Assets · · · · · · · $585.0K · · · ·
Total Assets 12-point trend, +230.7% $571M $594M $394M $191M $226M $271M $166M $185M $110M $130M $149M $173M
Accounts Payable 12-point trend, +989.7% $11M $9M $6M $10M $7M $7M $1M $982.0K $503.0K $225.0K $160.0K $1M
Accrued Liabilities 12-point trend, +3240.3% $51M $36M $40M $33M $30M $15M $8M $1M $926.0K $1M $1M $2M
Current Liabilities 12-point trend, +166.9% $112M $88M $108M $77M $46M $31M $28M $8M $7M $8M $7M $42M
Capital Leases 7-point trend, -34.3% $1M $2M $3M $4M $4M $5M $2M · · · · ·
Total Liabilities 7-point trend, +1035.2% $345M $313M $146M $111M $100M $60M $30M · · · · ·
Long-term Debt 2-point trend, +60.2% · · $82M $51M · · · · · · · ·
Total Debt 6-point trend, +397.2% $120M $118M $82M $51M $50M $24M · · · · · ·
Common Stock 12-point trend, +307.6% $640.0K $606.0K $545.0K $390.0K $324.0K $310.0K $200.0K $186.0K $160.0K $159.0K $159.0K $157.0K
Retained Earnings 12-point trend, -99.9% $-1.86B $-1.77B $-1.60B $-1.41B $-1.27B $-1.16B $-1.08B $-1.01B $-986M $-958M $-928M $-928M
AOCI 12-point trend, +420.2% $269.0K $261.0K $185.0K $-219.0K $-173.0K $78.0K $132.0K $-183.0K $-207.0K $-53.0K $-213.0K $-84.0K
Stockholders' Equity 12-point trend, +72.8% $226M $280M $248M $80M $126M $211M $135M $178M $104M $122M $142M $131M
Liabilities + Equity 12-point trend, +230.7% $571M $594M $394M $191M $226M $271M $166M $185M $110M $130M $149M $173M
Shares Outstanding 12-point trend, -99.6% 639,856 606,388,000 544,912,215 390,262,524 323,731,591 310,566,853 199,814,581 186,392,682 159,877,239 159,158,636 158,781,359 157,429,871
नकदी प्रवाह 15
GERN के लिए वार्षिक नकदी प्रवाह डेटा
मेट्रिक रुझान 202520242023202220212020201920182017201620152014
D&A 7-point trend, +640.6% $474.0K $546.0K $442.0K $288.0K $215.0K $158.0K $64.0K · · · · ·
Stock-based Comp 12-point trend, +248.1% $27M $31M $19M $8M $8M $7M $6M $6M $8M $8M $8M $8M
Restructuring 4-point trend, +1204.1% $17M $0 $0 · · · · · · · $1M ·
Operating Cash Flow 12-point trend, -1287.6% $-111M $-219M $-168M $-127M $-96M $-67M $-44M $-21M $-21M $-18M $-24M $9M
CapEx 10-point trend, +419.1% · $680.0K $830.0K $431.0K $207.0K $401.0K $413.0K $16.0K · $57.0K $90.0K $131.0K
Investing Cash Flow 11-point trend, +146813.7% $107M $-106M $-180M $62M $72M $-105M $27M $-78M $23M $9M $73.0K ·
Debt Issued 5-point trend, -100.0% $0 $121M $30M · $25M $24M · · · · · ·
Net Debt Issued 5-point trend, -100.0% $0 $35M $30M · $25M $24M · · · · · ·
Stock Issued 8-point trend, -79.3% · · · · $20M $4M $19M $86M $1M $1M $3M $98M
Net Stock Activity 8-point trend, -79.3% · · · · $20M $4M $19M $86M $1M $1M $3M $98M
Dividends Paid Flat — no change across 2 periods · · · · · · · · · · $0 $0
Financing Cash Flow 11-point trend, -12.0% $2M $334M $362M $87M $49M $168M $19M $93M $1M $1M $3M ·
Net Change in Cash 8-point trend, +93.3% $-1M $10M $14M $22M $25M · · · $4M $-8M $-22M ·
Free Cash Flow 10-point trend, -2478.8% · $-219M $-169M $-128M $-96M $-67M $-44M $-21M · $-18M $-24M $9M
Levered FCF · $-238M · · · · · · · · · ·
लाभप्रदता 6
GERN के लिए वार्षिक लाभप्रदता डेटा
मेट्रिक रुझान 202520242023202220212020201920182017201620152014
Operating Margin 9-point trend, -5313725.3% · · -81832.9% -23246.6% -8183.7% -30400.4% -15762.0% -2914.9% -2746.9% -497.3% -1.5% ·
Net Margin 9-point trend, -59762192.3% · · -77690.7% -23808.9% -8335.4% -29888.1% -14901.7% -2534.4% -2621.2% -479.3% 0.13% ·
EBITDA Margin 9-point trend, -5313725.3% · · -81832.9% -23246.6% -8183.7% -30400.4% -15762.0% -2914.9% -2746.9% -497.3% -1.5% ·
ROA 12-point trend, +51.8% -14.3% -35.3% -63.0% -68.1% -46.8% -34.7% -39.1% -18.3% -23.2% -21.2% 0.03% -29.7%
ROE 12-point trend, +8.1% -34.4% -61.0% -68.4% -150.8% -83.5% -34.1% -47.7% -15.0% -24.7% -22.3% 0.03% -37.5%
ROIC 2-point trend, +54.5% -19.9% -43.7% · · · · · · · · · ·
तरलता और शोधन क्षमता 5
GERN के लिए वार्षिक तरलता और शोधन क्षमता डेटा
मेट्रिक रुझान 202520242023202220212020201920182017201620152014
Current Ratio 12-point trend, +27.1% 4.7 5.6 3.2 2.4 4.1 6.5 5.0 22.0 14.7 14.8 17.5 3.7
Quick Ratio 12-point trend, -71.7% 1.0 1.3 0.6 0.7 0.8 0.3 0.5 1.4 14.5 14.6 17.1 3.6
Debt / Equity 6-point trend, +364.3% 0.5 0.4 0.3 0.6 0.4 0.1 · · · · · ·
LT Debt / Equity 6-point trend, +364.3% 0.5 0.4 0.1 0.4 0.4 0.1 · · · · · ·
Interest Coverage 5-point trend, +90.7% · -9.4 -23.3 -20.1 -30.5 -101.2 · · · · · ·
दक्षता 1
GERN के लिए वार्षिक दक्षता डेटा
मेट्रिक रुझान 202520242023202220212020201920182017201620152014
Asset Turnover 9-point trend, -99.6% · · 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 ·
प्रति शेयर 5
GERN के लिए वार्षिक प्रति शेयर डेटा
मेट्रिक रुझान 202520242023202220212020201920182017201620152014
Book Value / Share 12-point trend, -57.5% $0.35 $0.46 $0.46 $0.20 $0.39 $0.68 $0.68 $0.95 $0.65 $0.77 $0.90 $0.83
Revenue / Share 5-point trend, -99.8% · · $0.00 $0.00 · · · · $0.01 $0.04 $0.22 ·
Cash Flow / Share 7-point trend, -12.0% $-0.17 $-0.34 $-0.29 $-0.33 · · · · $-0.13 $-0.12 $-0.15 ·
Cash / Share 12-point trend, -55.4% $0.12 $0.13 $0.13 $0.15 $0.11 $0.03 $0.07 $0.06 $0.10 $0.08 $0.13 $0.27
EPS (TTM) 10-point trend, +43.5% $-0.13 $-0.27 $-0.32 $-0.37 $-0.35 $-0.28 · · $-0.18 $-0.19 $0.00 $-0.23
विकास दरें 2
GERN के लिए वार्षिक विकास दरें डेटा
मेट्रिक रुझान 202520242023202220212020201920182017201620152014
Revenue YoY 3-point trend, -113.4% · · -60.2% -57.2% 450.6% · · · · · · ·
Revenue CAGR 3Y · · -2.1% · · · · · · · · ·
मूल्यांकन (TTM) 17
GERN के लिए वार्षिक मूल्यांकन (TTM) डेटा
मेट्रिक रुझान 202520242023202220212020201920182017201620152014
Revenue TTM 12-point trend, +14135.6% $164M $30M $237.0K $596.0K $1M $253.0K $460.0K $1M $1M $6M $36M $1M
Net Income TTM 12-point trend, -134.1% $-84M $-175M $-184M $-142M $-116M $-76M $-69M $-27M $-28M $-30M $46.0K $-36M
Market Cap 12-point trend, +65.1% $845M $2.15B $1.15B $944M $395M $494M $272M $186M $288M $329M $769M $512M
Enterprise Value 6-point trend, +74.6% $887M $2.19B $1.16B $939M $410M $508M · · · · · ·
P/E 9-point trend, +28.1% -10.2 -13.1 -6.6 -6.5 -3.5 -5.7 · · -10.0 -10.9 · -14.1
P/S 12-point trend, -98.8% 5.1 72.5 4851.3 1584.6 283.5 1951.8 590.8 174.9 270.2 53.5 21.1 443.8
P/B 12-point trend, -4.5% 3.7 7.7 4.6 11.8 3.1 2.3 2.0 1.0 2.8 2.7 5.4 3.9
P / Tangible Book 6-point trend, +59.7% 3.7 7.7 4.6 11.8 3.1 2.3 · · · · · ·
P / Cash Flow 12-point trend, -113.9% -7.6 -9.8 -6.9 -7.4 -4.1 -7.4 -6.2 -8.9 -14.0 -17.9 -31.8 54.7
P / FCF 10-point trend, -117.6% · -9.8 -6.8 -7.4 -4.1 -7.4 -6.1 -8.9 · -17.9 -31.6 55.5
EV / EBITDA 6-point trend, -95.8% -12.9 -12.6 -6.0 -6.8 -3.6 -6.6 · · · · · ·
EV / FCF 5-point trend, -31.6% · -10.0 -6.9 -7.3 -4.3 -7.6 · · · · · ·
EV / Revenue 6-point trend, -99.7% 5.4 73.8 4901.6 1575.1 294.3 2007.6 · · · · · ·
Dividend Yield Flat — no change across 2 periods · · · · · · · · · · 0.00% 0.00%
Earnings Yield 10-point trend, -39.1% -9.8% -7.6% -15.2% -15.3% -28.7% -17.6% · · -10.0% -9.2% 0.00% -7.1%
Payout Ratio Flat — no change across 2 periods · · · · · · · · · · 0.00% 0.00%
Annual Payout Flat — no change across 2 periods · · · · · · · · · · $0 $0

वित्तीय विवरण आय विवरण, बैलेंस शीट, नकदी प्रवाह — वार्षिक, पिछले 5 वर्ष

आय विवरण
2025-12-312024-12-312023-12-312022-12-312021-12-31
राजस्व ——$237.0K$596.0K$1M
परिचालन मार्जिन % ——-81832.9%-23246.6%-8183.7%
शुद्ध आय $-84M$-175M$-184M$-142M$-116M
तनुकरणित EPS $-0.13$-0.27$-0.32$-0.37$-0.35
बैलेंस शीट
2025-12-312024-12-312023-12-312022-12-312021-12-31
ऋण / इक्विटी 0.50.40.30.60.4
वर्तमान अनुपात 4.75.63.22.44.1
त्वरित अनुपात 1.01.30.60.70.8
नकदी प्रवाह
2025-12-312024-12-312023-12-312022-12-312021-12-31
फ्री कैश फ्लो —$-219M$-169M$-128M$-96M

ताज़ा समाचार इस कंपनी का उल्लेख करने वाली हालिया सुर्खियां

मेरे मेट्रिक्स आपकी व्यक्तिगत वॉचलिस्ट — पूर्ण फंडामेंटल से चयनित पंक्तियाँ

📊

उन मेट्रिक्स को चुनें जो आपके लिए मायने रखते हैं — ऊपर पूर्ण फंडामेंटल में किसी भी पंक्ति के बगल में ➕ पर क्लिक करें।

आपका चयन सहेजा गया है और यह सभी टिकर में आपके साथ रहता है।

संस्थागत मालिक (13F) 279 फाइलर्स · $500.1M कुल · तिथि अनुसार 30 जून 2026

संस्थान जो अपनी तिमाही SEC फॉर्म 13F में इस स्टॉक को होल्ड करने की रिपोर्ट करते हैं। केवल लॉन्ग पोजीशन; एक ही फाइलर अलग-अलग ऑप्शन लेग्स के लिए दो बार दिखाई दे सकता है। बड़े ऑफसेटिंग पुट/कॉल लेग्स आमतौर पर मार्केट-मेकिंग या हेज्ड इन्वेंट्री को दर्शाते हैं, न कि दिशात्मक विश्वास को।

संस्थागत गतिविधि — Q2 2026 बनाम पिछली तिमाही
नई स्थितियाँ बाहर निकली पोजीशन बढ़ाया घटा हुआ शुद्ध शेयर परिवर्तन
45 (+8 पिछली तिमाही की तुलना में) 29 (-7 पिछली तिमाही की तुलना में) 87 (-1 पिछली तिमाही की तुलना में) 64 (+3 पिछली तिमाही की तुलना में) -23.4M

Q1 2026 की तुलना में। SEC फॉर्म 13F फाइलिंग तिमाही के अंत के 45 दिनों के भीतर देय होती है, साथ ही देर से फाइल करने वालों के लिए एक छोटा बफर भी होता है — उस विंडो के भीतर आने वाली तिमाहियों को सबसे हालिया पूरी तरह से रिपोर्ट की गई जोड़ी के पक्ष में छोड़ दिया जाता है।

संस्था मूल्य शेयर % ट्रैक किए गए 13F का प्रकार
RA CAPITAL MANAGEMENT, L.P. $54796481 42809751 10.96% शेयर
Soleus Capital Management, L.P. $54795084 42808659 10.96% शेयर
STATE STREET CORP $45896539 35856671 9.18% शेयर
VANGUARD CAPITAL MANAGEMENT LLC $34880275 27250215 6.97% शेयर
CITADEL ADVISORS LLC $29706728 23208381 5.94% शेयर
Clearbridge Investments, LLC $25150531 19648853 5.03% शेयर
Eversept Partners, LP $23958300 18717422 4.79% शेयर
GOLDMAN SACHS GROUP INC $20398367 15936224 4.08% शेयर
GEODE CAPITAL MANAGEMENT, LLC $16055546 12540400 3.21% शेयर
Nantahala Capital Management, LLC $15648000 12225000 3.13% शेयर
VANGUARD PORTFOLIO MANAGEMENT LLC $13840125 10812598 2.77% शेयर
Vivo Capital, LLC $11099900 8671797 2.22% शेयर
MILLENNIUM MANAGEMENT LLC $10383702 8112267 2.08% शेयर
Kynam Capital Management, LP $8750487 6836318 1.75% शेयर
Candriam S.C.A. $7147270 5589182 1.43% शेयर
FMR LLC $7040147 5500115 1.41% शेयर
Pale Fire Capital SE $6793221 5307204 1.36% शेयर
RENAISSANCE TECHNOLOGIES LLC $5861120 4579000 1.17% शेयर
SEGALL BRYANT & HAMILL, LLC $5741509 4485554 1.15% शेयर
TWO SIGMA INVESTMENTS, LP $5514257 4308013 1.10% शेयर
CHARLES SCHWAB INVESTMENT MANAGEMENT INC $5484367 4284662 1.10% शेयर
TORONTO DOMINION BANK $5420800 4235000 1.08% शेयर
Point72 Asset Management, L.P. $5177857 4045201 1.04% शेयर
VANGUARD FIDUCIARY TRUST CO $5073361 3963563 1.01% शेयर
Qube Research & Technologies Ltd $4302828 3361584 0.86% शेयर
PANAGORA ASSET MANAGEMENT INC $3762520 2939469 0.75% शेयर
BANK OF AMERICA CORP /DE/ $3386083 2645377 0.68% शेयर
ExodusPoint Capital Management, LP $3233466 2526145 0.65% शेयर
BNP PARIBAS FINANCIAL MARKETS $3093044 2416441 0.62% शेयर
EDMOND DE ROTHSCHILD HOLDING S.A. $2982400 2330000 0.60% शेयर
JANUS HENDERSON GROUP PLC $2948470 1978839 0.59% शेयर
NAN FUNG TRINITY (HK) LTD $2846144 2223550 0.57% शेयर
SUSQUEHANNA INTERNATIONAL GROUP, LLP $1980466 1547239 0.40% शेयर
World Investment Advisors $1540331 1033779 0.31% शेयर
MOORE CAPITAL MANAGEMENT, LP $1525684 1191941 0.31% शेयर
Kodai Capital Management LP $1420015 893091 0.28% शेयर
Seven Fleet Capital Management LP $1353252 1057228 0.27% शेयर
Virtus Investment Advisers, LLC $1294337 1011201 0.26% शेयर
Voleon Capital Management LP $1286385 1004988 0.26% शेयर
Swiss National Bank $1233920 964000 0.25% शेयर
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM $1098343 737143 0.22% शेयर
CITIGROUP INC $1016225 793926 0.20% शेयर
RHUMBLINE ADVISERS $937030 732065 0.19% शेयर
J. Goldman & Co LP $911519 712124 0.18% शेयर
Man Group plc $891736 696669 0.18% शेयर
ALLIANCEBERNSTEIN L.P. $852013 571821 0.17% शेयर
SummitTX Capital, L.P. $840991 657024 0.17% शेयर
ALPS ADVISORS INC $833381 651079 0.17% शेयर
Exome Asset Management LLC $798779 624046 0.16% शेयर
FRANKLIN RESOURCES INC $792180 618891 0.16% शेयर
Rafferty Asset Management, LLC $776243 606440 0.16% शेयर
Arax Advisory Partners $774782 605298 0.15% शेयर
SUSQUEHANNA INTERNATIONAL GROUP, LLP $760704 594300 0.15% पुट ऑप्शन
AMERIPRISE FINANCIAL INC $740238 578311 0.15% शेयर
Lion Point Capital, LP $739840 578000 0.15% शेयर
Summit X, LLC $697653 494789 0.14% शेयर
Bank of New York Mellon Corp $687999 537499 0.14% शेयर
Squarepoint Ops LLC $684110 534461 0.14% शेयर
Quadrature Capital Ltd $670802 524064 0.13% शेयर
Nvest Financial, LLC $661952 517150 0.13% शेयर
WELLS FARGO & COMPANY/MN $653320 510406 0.13% शेयर
ADAR1 Capital Management, LLC $647446 505817 0.13% शेयर
Private Advisor Group, LLC $643686 502878 0.13% शेयर
BlackRock, Inc. $637309 497898 0.13% शेयर
Verdad Advisers, LP $632577 494201 0.13% शेयर
XTX Topco Ltd $593788 463897 0.12% शेयर
CITADEL ADVISORS LLC $549760 429500 0.11% पुट ऑप्शन
Inspire Investing, LLC $520944 349627 0.10% शेयर
TWO SIGMA ADVISERS, LP $481861 365046 0.10% शेयर
MetLife Investment Management, LLC $419818 327983 0.08% शेयर
RAYMOND JAMES FINANCIAL INC $418721 327126 0.08% शेयर
VANGUARD GROUP INC $413314 313117 0.08% शेयर
VANGUARD ASSET MANAGEMENT, Ltd $400790 313117 0.08% शेयर
PROFUND ADVISORS LLC $392430 306586 0.08% शेयर
MOODY NATIONAL BANK TRUST DIVISION $380421 297204 0.08% शेयर
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. $329782 257642 0.07% शेयर
MML INVESTORS SERVICES, LLC $317320 247906 0.06% शेयर
Mitsubishi UFJ Trust & Banking Corp $288758 225592 0.06% शेयर
Invesco Ltd. $284978 222639 0.06% शेयर
Vanguard Global Advisers, LLC $281386 219833 0.06% शेयर
DIVERSIFIED TRUST CO $279718 218530 0.06% शेयर
ALLSTATE CORP $269037 210185 0.05% शेयर
STATE OF WISCONSIN INVESTMENT BOARD $268279 209593 0.05% शेयर
Mason & Associates Inc $256399 200312 0.05% शेयर
Verition Fund Management LLC $256000 200000 0.05% कॉल ऑप्शन
Cresset Asset Management, LLC $255625 199707 0.05% शेयर
JANE STREET GROUP, LLC $246912 192900 0.05% कॉल ऑप्शन
ProShare Advisors LLC $241398 188592 0.05% शेयर
LPL Financial LLC $233494 182417 0.05% शेयर
Verition Fund Management LLC $222322 173689 0.04% शेयर
NEW YORK STATE COMMON RETIREMENT FUND $219460 171453 0.04% शेयर
Headlands Technologies LLC $204202 159533 0.04% शेयर
State of New Jersey Common Pension Fund D $198830 155336 0.04% शेयर
LOS ANGELES CAPITAL MANAGEMENT LLC $197696 154450 0.04% शेयर
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC $196643 131975 0.04% शेयर
Police & Firemen's Retirement System of New Jersey $196315 153371 0.04% शेयर
MANUFACTURERS LIFE INSURANCE COMPANY, THE $190601 148907 0.04% शेयर
STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM $181916 142122 0.04% शेयर
EntryPoint Capital, LLC $176184 137644 0.04% शेयर
INTECH INVESTMENT MANAGEMENT LLC $175196 136872 0.04% शेयर

कंपनी के अंदरूनी सूत्र 46 इनसाइडर्स · 27 अधिकारी · 21 निदेशक

अंदरूनी भूमिका अंतिम गतिविधि शेयरों का स्वामित्व खरीद 12m बिक्री 12m नेट 12m
Harout Semerjian President and CEO 7 अगस्त 2025 A — 0 0 $0
Dawn Carter Bir Interim President and CEO 21 मई 2025 A — 0 0 $0
John A Scarlett Chairman, President and CEO 27 फ़रवरी 2025 P 12500 0 0 $0
David Greenwood President, Interim CEO, CFO 14 जून 2011 S 754031 0 0 $0
Thomas Okarma President and CEO 9 जुलाई 2010 A 774560 0 0 $0
Michelle Robertson EVP, Chief Financial Officer 18 फ़रवरी 2025 A — 0 0 $0
Olivia Kyusuk Bloom EVP, Chief Financial Officer 15 अगस्त 2023 A 74588 0 0 $0
Graham K Cooper EVP, Bus Dev & CFO 17 मई 2012 A — 0 0 $0
Alan Colowick President, Oncology 2 जनवरी 2008 I 3028 0 0 $0
Andrew J Grethlein EVP, Chief Operating Officer 18 फ़रवरी 2025 A 0 0 0 $0
James Ziegler EVP, Chief Commercial Officer 27 फ़रवरी 2025 P 100000 0 0 $0
Scott Alan Samuels EVP, Chief Legal Officer 27 फ़रवरी 2025 P 26682 0 0 $0
Joseph Eid EVP, Research and Development 11 नवमबर 2024 A — 0 0 $0
Faye Feller EVP, Chief Medical Officer 10 जून 2024 M 0 0 0 $0
Anil Kapur EVP, Corp Strategy & CCO 10 जून 2024 M 0 0 0 $0
Aleksandra Rizo EVP, Chief Medical Officer 16 फ़रवरी 2022 A — 0 0 $0
Stephen Rosenfield EVP, Chief Legal Off & Sec 16 फ़रवरी 2022 A 0 0 0 $0
Melissa Kelly Behrs EVP, Chief Business Officer 2 फ़रवरी 2021 A 0 0 0 $0
Craig C Parker EVP, Corp Dev & Sci Affairs 10 फ़रवरी 2014 A — 0 0 $0
Stephen Michael Kelsey EVP, R&D, Chief Med Officer 3 मई 2013 D 62272 0 0 $0
David Earp SVP, Corp Transactions 30 मई 2012 S 467406 0 0 $0
Katharine E. Spink SVP Alliance Mgmt & Operations 14 जून 2011 S 328561 0 0 $0
Jane Lebkowski SVP, Chief Scientific Officer 14 जून 2011 S 568154 0 0 $0
Melanie I Nallicheri SVP Corp Dev 20 मई 2011 A 195000 0 0 $0
Fabio M Benedetti SVP, Chief Med Off, Oncology 29 मई 2009 A 80560 0 0 $0
Calvin Harley VP, CSO Telomerase Tech 29 मई 2009 A 134036 0 0 $0
William Stempel VP and General Counsel 27 मई 2004 A 6521 0 0 $0
Robert J. Spiegel निदेशक 30 जून 2026 A 205810 0 0 $0
John F Mcdonald निदेशक 21 मई 2025 A — 0 0 $0
Elizabeth G. O'Farrell निदेशक 21 मई 2025 A 26220 0 0 $0
Susan Molineaux निदेशक 21 मई 2025 A 130527 0 0 $0
Gaurav Aggarwal निदेशक 21 मई 2025 A 1970 0 0 $0
Bryan V Lawlis निदेशक 21 मई 2025 A 13300 0 0 $0
Karin Eastham निदेशक 13 जनवरी 2023 M 109047 0 0 $0
Daniel Bradbury निदेशक 29 मार्च 2019 A 51323 0 0 $0
Hoyoung Huh निदेशक 15 मई 2018 A 154301 0 0 $0
Thomas Hofstaetter निदेशक 18 मार्च 2015 M 26564 0 0 $0
Thomas Kiley निदेशक 22 मई 2013 D 171911 0 0 $0
Edward V Fritzky निदेशक 22 मई 2013 D 186511 0 0 $0
Alexander E Barkas निदेशक 20 मई 2011 A 353122 0 0 $0
Charles J Homcy निदेशक 11 मई 2011 A 62751 0 0 $0
ZENNER PATRICK J निदेशक 19 मई 2010 A 73710 0 0 $0
John Peter Walker निदेशक 30 जनवरी 2009 M 39119 0 0 $0
Robert B Stein निदेशक 23 सितमबर 2003 M 0 0 0 $0
GERON CORP 10% मालिक 28 मई 2014 J 0 0 0 $0
MERIX BIOSCIENCE INC 10% मालिक 16 अगस्त 2004 S 4541100 0 0 $0

SEC फॉर्म 3/4/5 फाइलिंग से अंदरूनी सूत्र; नेट = केवल ओपन-मार्केट P/S

कार्यकर्ता और 5%+ मालिक 3 होल्डिंग्स

जिन निवेशकों ने SEC शेड्यूल 13D दाखिल किया है — जारीकर्ता को प्रभावित करने के इरादे से 5% से अधिक लाभकारी स्वामित्व (कार्यकर्ता दांव, बोर्ड अभियान, M&A)। प्रत्येक पंक्ति उस फाइलर की स्थिति की सबसे हालिया ज्ञात स्थिति दिखाती है।

फाइलर दाखिल किया दांव स्थिति उद्देश्य फाइलिंग
3 फ़रवरी 2023 — प्रारंभिक फाइलिंग — SEC
Growth Equity Opportunities 17, LLC, New Enterprise Associates 17, L.P., NEA Partners 17, L.P., NEA 17 GP, LLC, Forest Baskett, Ali Behbahani, Carmen Chang, Anthony A. Florence, Jr., Liza Landsman, Mohamad H. Makhzoumi, Joshua Makower, Edward T. Mathers, Scott D. Sandell, Peter W. Sonsini, Paul Walker, Rick Yang 4 जून 2020 — प्रारंभिक फाइलिंग निष्क्रिय निवेश SEC
G ERON C ORPORATION ×3 फाइलिंग 19 अगस्त 2014 — प्रारंभिक फाइलिंग — SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

ईटीएफ स्वामित्व 34 ETFs द्वारा धारित

वजन केवल प्रत्यक्ष इक्विटी होल्डिंग्स (N-PORT) को दर्शाता है; लीवरेज्ड या डेरिवेटिव-आधारित फंड में अतिरिक्त स्वैप एक्सपोजर हो सकता है जो नहीं दिखाया गया है।

फंड भार इकाइयाँ तिथि अनुसार स्रोत
BBP · ETFis Series Trust I 1.81% 695861 NS 30 अप्रैल 2026 N-PORT
JSML · Janus Detroit Street Trust 0.90% 1855332 NS 30 अप्रैल 2026 N-PORT
SBIO · ALPS ETF Trust 0.51% 660249 NS 31 मई 2026 N-PORT
LABU · Direxion Shares ETF Trust 0.28% 951040 NS 30 अप्रैल 2026 N-PORT
ESSC · Strategy Shares 0.16% 27159 NS 30 अप्रैल 2026 N-PORT
BIB · ProShares Trust 0.04% 23602 NS 31 मई 2026 N-PORT
RSSL · Global X Funds 0.03% 236763 NS 30 अप्रैल 2026 N-PORT
ITWO · ProShares Trust 0.02% 25707 NS 31 मई 2026 N-PORT
SCHA · SCHWAB STRATEGIC TRUST 0.01% 2555103 NS 31 मई 2026 N-PORT
FHLC · FIDELITY COVINGTON TRUST 0.01% 230599 NS 30 अप्रैल 2026 N-PORT
TILT · FlexShares Trust 0.01% 144298 NS 30 अप्रैल 2026 N-PORT
UWM · ProShares Trust 0.01% 20105 NS 31 मई 2026 N-PORT
URTY · ProShares Trust 0.01% 20335 NS 31 मई 2026 N-PORT
ONEQ · Fidelity Commonwealth Trust 0.00% 348551 NS 31 मई 2026 N-PORT
MSSM · MORGAN STANLEY PATHWAY FUNDS 0.00% 23306 NS 31 मई 2026 N-PORT
HDG · ProShares Trust 0.00% 511 NS 31 मई 2026 N-PORT
SCHB · SCHWAB STRATEGIC TRUST 0.00% 317140 NS 31 मई 2026 N-PORT
VXF · VANGUARD INDEX FUNDS — — 15 जुलाई 2026 दैनिक
VTI · VANGUARD INDEX FUNDS — — 15 जुलाई 2026 दैनिक
VTWO · VANGUARD SCOTTSDALE FUNDS — — 15 जुलाई 2026 दैनिक
VTWG · VANGUARD SCOTTSDALE FUNDS — — 15 जुलाई 2026 दैनिक
VTHR · VANGUARD SCOTTSDALE FUNDS — — 15 जुलाई 2026 दैनिक
ITOT · iShares Trust — — 5 अगस्त 2026 दैनिक
IWV · iShares Trust — — 18 अगस्त 2026 दैनिक
IWO · iShares Trust — — 18 अगस्त 2026 दैनिक
IWM · iShares Trust — — 18 अगस्त 2026 दैनिक
IBB · iShares Trust — — 18 अगस्त 2026 दैनिक
PRFZ · Invesco Exchange-Traded Fund Trust — — 13 जुलाई 2026 दैनिक
VHT · VANGUARD WORLD FUND — — 20 जुलाई 2026 दैनिक
ISCB · iShares Trust — — 5 अगस्त 2026 दैनिक
ISCV · iShares Trust — — 5 अगस्त 2026 दैनिक
WSML · iShares Trust — — 5 अगस्त 2026 दैनिक
IBBQ · Invesco Exchange-Traded Fund Trust … — — 20 जुलाई 2026 दैनिक
QQQS · Invesco Exchange-Traded Fund Trust … — — 5 अगस्त 2026 दैनिक